In the recently published ‘Accurate Congenital Heart Disease Model Generation for 3D Printing,’ researchers explore 3D printing for diagnosis, treatment, and planning in congenital heart disease (CHD) patients. CHD usually presents itself at birth and can be difficult to analyze, even with 3D medical images—and despite many different studies by scientists around the world. The researchers note that 3D printing has been ‘widely adopted’ in clinical settings lately, offering for improvements in the following:
- Clinical decision making
- Interventional planning
- Communication between physicians and patients
- Improving medical education
In the dataset for this research, combining deep learning and graph matching for whole heart and great vessel segmentation in CHD, patients ranged in age from one month to 21 years old—while most were from one month to two years old. Out of 16 cases, the study covers 14 types of CHD to include the most common 8, which are atrial septal defect (ASD), atrio-ventricular septal defect (AVSD), patent ductus arteriosus (PDA), pulmonary stenosis (PS), ventricular septal defect (VSD), co-arctation (CA), Tetrology of Fallot (ToF), and transposition of great arteries (TGA).
The researchers explain that there has already been a prolific amount of research using the multi-modality whole heart segmentation method, with ‘state-of-the-art performance’ found in combining 3D U-net for segmentation and a simple convolutional neural network for label position prediction. Another technique involves using the basic simple convolutional neural network for label position prediction, while another handles blood pool and myocardium in blood pool segmentation.
“Considering the significant variations in heart structures and great vessel connections in CHD, almost all the existing methods cannot effectively perform whole heart and great vessels segmentation in CHD,” state the researchers.
Motivated instead by the promise of graph matching, they used deep learning and graph matching, collecting 68 CT images overall, with an 11.9 percent higher Dice score. The framework consisted of:
- Region of interest cropping
- Chambers and myocardium segmentation
- Blood pool segmentation
- Chambers and myocardium refinement
- Graph matching
Segmentation results were printed on a Sailner J501Pro for evaluation—a process that took the researchers about three to four hours. The researchers assessed the 3D printed model as correct, and with clear shape and connections, with minor refinements necessary such as thin coronary vessels.
“We also printed out part of the segmentation results with minor manual refinement and showed that it can be applied to clinic use,” concluded the researchers.
3D printed models have proven to be more than just helpful in many different areas of the medical realm, especially as they are able to offer so much in terms of education not only for students but also for patients and their families, as well as helping in the preoperative stages—and during the actual operation too with surgical planning models.[Source / Images: ‘Accurate Congenital Heart Disease Model Generation for 3D Printing’]
You May Also Like
3D Printing News Briefs, October 9, 2021: Automation, Bioprinting, & More
We’re starting with new materials in today’s 3D Printing News Briefs, then moving on to automation, bioprinting, and business. B9Creations introduced new resins for 3D printed molds and production parts,...
Bioprinted Brain Cells Made Possible with Laser-Based 3D Printing
Scientists from the Université de Montréal have published a study detailing the ability to bioprint adult brain cells. Key to the research was a new laser-assisted technology that made it...
Cellink-Organovo Lawsuit Over Bioprinting Patents is Far From Over
In the highly competitive biotechnology and pharmaceutical industries, hardware manufacturers are under a lot of pressure to provide the best, most efficient, and fastest platforms for researchers. Bioprinting, in particular,...
Can Fluicell’s Bioprinted Tissue Help Treat Type 1 Diabetes?
As Swedish bioprinter manufacturer Fluicell prepares to enter the regenerative medicine market through its BioRej Advance program, it focuses on developing therapeutic products based on bioprinted transplantable microtissues targeting important...
View our broad assortment of in house and third party products.